Daniel Lorenzo1, Josep Maria Piulats2, María Ochoa2, Luis Arias3, Cristina Gutiérrez4, Jaume Català3, Estefanía Cobos3, Pere Garcia-Bru3, Bruno Dias3, Noel Padrón-Pérez3, Josep Maria Caminal3. 1. Department of Ophthalmology, Bellvitge University Hospital, Feixa Llarga, s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. dlorenzo@bellvitgehospital.cat. 2. Department of Oncology, Catalan Institute of Oncology, Barcelona, Spain. 3. Department of Ophthalmology, Bellvitge University Hospital, Feixa Llarga, s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain. 4. Department of Brachytherapy, Catalan Institute of Oncology, Barcelona, Spain.
Abstract
PURPOSE: To determine the clinical factors that influence survival in patients with metastatic uveal melanoma. STUDY DESIGN: Single-center, retrospective review of patients' medical records. METHODS: The following data of ninety-nine consecutive patients (49 men, 50 women) with metastatic uveal melanoma were registered: patient demographics; primary tumor characteristics; features of first melanoma-related metastasis; symptoms and patient status at distant disease debut and metastasis treatment. Overall survival was analyzed by Kaplan-Meier estimates. A Cox proportional hazards regression model was applied to identify independent predictors associated with survival. RESULTS: Mean patient age at metastatic diagnosis was 60.7 years (standard deviation, 12.8). The liver was the first metastatic site in most (92.9%) cases. The median disease-free interval was 26 months (interquartile range, 34). Median overall survival after detection of the first metastasis was 8 months (interquartile range, 14). The baseline characteristics of the primary uveal melanoma were not associated with survival in patients with stage IV disease. In the multivariate analysis, the following factors at first metastatic diagnosis were associated with improved overall survival: disease-free interval > 36 months; better performance status; and normal serum lactate dehydrogenase and gamma glutamyl transpeptidase levels. Overall survival was not influenced by specific metastatic treatment. CONCLUSION: Although metastatic uveal melanoma has a poor prognosis, this study reveals the existence of several independent prognostic factors for prolonged overall survival. These findings may help improve survival estimates in patients with advanced disease.
PURPOSE: To determine the clinical factors that influence survival in patients with metastatic uveal melanoma. STUDY DESIGN: Single-center, retrospective review of patients' medical records. METHODS: The following data of ninety-nine consecutive patients (49 men, 50 women) with metastatic uveal melanoma were registered: patient demographics; primary tumor characteristics; features of first melanoma-related metastasis; symptoms and patient status at distant disease debut and metastasis treatment. Overall survival was analyzed by Kaplan-Meier estimates. A Cox proportional hazards regression model was applied to identify independent predictors associated with survival. RESULTS: Mean patient age at metastatic diagnosis was 60.7 years (standard deviation, 12.8). The liver was the first metastatic site in most (92.9%) cases. The median disease-free interval was 26 months (interquartile range, 34). Median overall survival after detection of the first metastasis was 8 months (interquartile range, 14). The baseline characteristics of the primary uveal melanoma were not associated with survival in patients with stage IV disease. In the multivariate analysis, the following factors at first metastatic diagnosis were associated with improved overall survival: disease-free interval > 36 months; better performance status; and normal serum lactate dehydrogenase and gamma glutamyl transpeptidase levels. Overall survival was not influenced by specific metastatic treatment. CONCLUSION: Although metastatic uveal melanoma has a poor prognosis, this study reveals the existence of several independent prognostic factors for prolonged overall survival. These findings may help improve survival estimates in patients with advanced disease.
Authors: Daniël P de Bruyn; Aaron B Beasley; Robert M Verdijk; Natasha M van Poppelen; Dion Paridaens; Ronald O B de Keizer; Nicole C Naus; Elin S Gray; Annelies de Klein; Erwin Brosens; Emine Kiliç Journal: Biomedicines Date: 2022-02-21
Authors: Christine D M Roelofsen; Annemijn P A Wierenga; Sjoerd van Duinen; Robert M Verdijk; Jaco Bleeker; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager Journal: Ocul Oncol Pathol Date: 2020-12-15
Authors: Mark R Middleton; Cheryl McAlpine; Victoria K Woodcock; Pippa Corrie; Jeffrey R Infante; Neil M Steven; Thomas R Jeffry Evans; Alan Anthoney; Alexander N Shoushtari; Omid Hamid; Avinash Gupta; Antonella Vardeu; Emma Leach; Revashnee Naidoo; Sarah Stanhope; Sion Lewis; Jacob Hurst; Ita O'Kelly; Mario Sznol Journal: Clin Cancer Res Date: 2020-08-18 Impact factor: 13.801
Authors: Gaurav Garg; Paul T Finger; Tero T Kivelä; E Rand Simpson; Brenda L Gallie; Svetlana Saakyan; Anush G Amiryan; Vladimir Valskiy; Kimberly J Chin; Ekaterina Semenova; Stefan Seregard; Maria Filì; Matthew Wilson; Barrett Haik; Josep Maria Caminal; Jaume Catala-Mora; Cristina Gutiérrez; David E Pelayes; Anibal Martin Folgar; Martine Johanna Jager; Mehmet Doğrusöz; Gregorius P M Luyten; Arun D Singh; Shigenobu Suzuki Journal: Br J Ophthalmol Date: 2021-01-15 Impact factor: 4.638